Efficacy and Safety of Dapagliflozin in Acute Heart Failure
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This is a randomized trial of the addition of dapagliflozin to patients with diabetes
hospitalized with acute decompensated heart failure (ADHF). Participants will be recruited
following an initial standard evaluation in the ED and randomized within 24 hours of
presentation for ADHF in a 1:1 fashion to protocolized diuretic therapy or dapagliflozin +
protocolized diuretic therapy.